RecruitingNCT05914987

Determining Individualized Cancer Therapy in Pancreatic Cancer

Profile-Related Evidence Determining Individualized Cancer Therapy in Pancreatic Cancer (PREDICT-PANC)


Sponsor

Medical College of Wisconsin

Enrollment

1,000 participants

Start Date

Dec 4, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This is a non-therapeutic exploratory observational precision oncology study designed to collect and analyze data that demonstrate the clinical efficacy and tolerability of personalized treatments based on molecular tumor profiling assessments (i.e., matched therapy) in adult pancreatic cancer patients. Patient medical records, obtained both retrospectively and prospectively, will be examined for results of molecular profiling obtained through standard of care testing to help understand how well molecular testing might predicts response to therapy. Patient demographic and outcome parameters to be evaluated include, but are not limited to, tumor response, time to treatment failure, patient survival, and toxicity.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting tissue and blood samples from pancreatic cancer patients to build individualized cancer profiles — analyzing genes, proteins, and tumor characteristics — to match each patient with the most effective treatment. **You may be eligible if...** - You are 18 or older - You have a confirmed pathological diagnosis of pancreatic cancer - You are able to understand and sign a consent form **You may NOT be eligible if...** - You are under 18 - Your primary cancer is not pancreatic cancer - You are unable or unwilling to provide consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTargeted Therapy

Approved interventions based on the subject's genomic profile will be provided to investigators for consideration for anti-tumor therapy.


Locations(1)

Froedtert Hospital and the Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05914987


Related Trials